University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carolina Urologic Research Center, Myrtle Beach, SC, USA.
BJU Int. 2024 May;133(5):524-531. doi: 10.1111/bju.16310. Epub 2024 Mar 4.
To provide a practical review of immune-related adverse events (irAEs) that may be encountered in uro-oncology patients.
We conducted a literature review of studies reporting irAEs including articles published through September 2023 for uro-oncology patients and the potential relevancy for the practicing urologist.
Immunotherapy has revolutionised cancer treatment, extending its impact to urological malignancies including for patients with urothelial, kidney, and prostate cancers. Immuno-oncology (IO) compounds have achieved measurable and durable responses in these cancers. Urologists, choosing to administer or co-manage IO patient care, should be prepared to understand, evaluate, and treat irAEs. This review discusses the spectrum of irAEs that can be encountered. Ongoing trials are exploring the use of immunotherapy at earlier stages of uro-oncological diseases, thus underscoring the evolving landscape of urological cancer treatment. Paradoxically, some data suggests that the occurrence of irAEs is associated with improved oncological outcomes.
Immune-related AEs, while manageable, may be life-threatening and require lifelong therapy. A thorough understanding of AEs and toxicity of a novel drug class is imperative.
提供在泌尿肿瘤学患者中可能遇到的免疫相关不良事件（irAEs）的实用综述。
我们对报告包括发表至 2023 年 9 月的泌尿肿瘤学患者的 irAEs 研究的文献进行了综述，并评估了其对执业泌尿科医生的潜在相关性。
免疫疗法彻底改变了癌症治疗，将其影响扩展到包括尿路上皮癌、肾癌和前列腺癌在内的泌尿系统恶性肿瘤。免疫肿瘤学（IO）药物在这些癌症中取得了可衡量和持久的反应。选择管理 IO 患者护理的泌尿科医生应准备好理解、评估和治疗 irAEs。本综述讨论了可能遇到的 irAEs 谱。正在进行的试验正在探索在泌尿肿瘤学疾病的早期阶段使用免疫疗法，从而强调了泌尿外科癌症治疗的不断发展。矛盾的是，一些数据表明 irAEs 的发生与改善的肿瘤学结果相关。
免疫相关不良事件虽然可以控制，但可能危及生命，需要终身治疗。彻底了解新型药物类别的不良事件和毒性至关重要。
